RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

NCT04159974 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Adenocarcinoma

Interventions

DRUG: Durvalumab 50 MG/ML
DRUG: Tremelimumab

Sponsor

University of Cologne

Collaborators

[object Object]